CollPlant Biotechnologies (CLGN) Accumulated Depreciation (2024 - 2025)
CollPlant Biotechnologies (CLGN) reported Accumulated Depreciation of $7.9 million for Q4 2025, up 12.16% on a YoY basis from $7.0 million in Q4 2024, and up 12.16% quarter-over-quarter from $7.0 million in Q4 2024.
CollPlant Biotechnologies (CLGN) Accumulated Depreciation (2024 - 2025) Analysis & Trends
CollPlant Biotechnologies has reported Accumulated Depreciation for 2 years, with the latest figure at $7.9 million in Q4 2025.
- For the quarter ending Q4 2025, Accumulated Depreciation rose 12.16% year-over-year to $7.9 million; the trailing twelve-month figure through Dec 2025 stood at $7.9 million (up 12.16% YoY), and the FY2025 full-year result was $7.9 million, up 12.16% from the prior year.
- Accumulated Depreciation for Q4 2025 stood at $7.9 million, up from $7.0 million in the prior quarter.
- The five-year high for Accumulated Depreciation was $7.9 million in Q4 2025, with the low at $7.0 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | CollPlant Biotechnologies | 7.20 Mn | 7.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.88 Mn |
| Dec 31, 2024 | 7.02 Mn |